Index
RUT
Market Cap
1.46B
Enterprise Value
1.51B
Income
37.73M
Sales
743.30M
Book/sh
17.85
Cash/sh
7.37
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
829
IPO
Feb 03, 2011
P/E
39.48
Forward P/E
10.39
PEG
0.50
P/S
1.97
P/B
2.04
P/C
4.95
P/FCF
8.65
EV/EBITDA
13.19
EV/Sales
2.03
Quick Ratio
3.65
Current Ratio
4.68
Debt/Eq
0.48
LT Debt/Eq
0.46
Option/Short
Yes / Yes
EPS (ttm)
0.92
EPS next Y
3.51
EPS next Q
0.75
EPS this Y
9.40%
EPS next Y
21.07%
EPS next 5Y
20.79%
EPS past 3/5Y
-22.97% -45.77%
Sales past 3/5Y
2.89% 11.07%
EPS Y/Y TTM
101.62%
Sales Y/Y TTM
3.70%
EPS Q/Q
471.60%
Sales Q/Q
-1.59%
Insider Own
3.75%
Insider Trans
-1.66%
Inst Own
110.29%
Inst Trans
-7.83%
ROA
3.02%
ROE
5.24%
ROIC
3.62%
Gross Margin
71.29%
Oper. Margin
4.17%
Profit Margin
5.08%
SMA20
0.15%
SMA50
16.90%
SMA200
42.12%
Trades
Shs Outstand
39.90M
Shs Float
38.59M
52W High
36.67 -0.56%
52W Low
18.80 93.94%
Volatility
0.12% 0.15%
ATR (14)
0.28
RSI (14)
82.71
Beta
0.22
Rel Volume
1.53
Avg Volume
1.27M
Volume
1,944,831
Perf Week
0.08%
Perf Month
0.36%
Perf Quarter
56.88%
Perf Half Y
61.04%
Perf YTD
40.88%
Perf Year
54.36%
Perf 3Y
29.66%
Perf 5Y
-36.08%
Perf 10Y
-0.92%
Prev Close
36.46
Price
36.46
Change %
0.00%
Analysts 12 incl. previous ratings
Rating Distribution 6 Buy · 5 Hold · 1 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Sep 23, 2026 Initiated O Oppenheimer
Outperform $32 -12.2% Sep 09, 2026 Initiated L Leerink Partners
Market Perform $28 -23.2% Aug 17, 2026 Resumed T Truist
Buy $30 -17.7% Dec 09, 2025 Initiated B Barclays
Equal Weight $27 -25.9% Nov 17, 2025 Initiated H H.C. Wainwright
Buy Jul 25, 2025 Upgrade T Truist
Hold → Buy $30 -17.7% Jan 30, 2025 Upgrade T Truist
Sell → Hold $8 → $25 -31.4% Aug 13, 2024 Downgrade T Truist
Buy → Sell $30 → $8 -78.1% Aug 12, 2024 Downgrade R RBC Capital Mkts
Outperform → Sector Perform $37 → $14 -61.6% Aug 12, 2024 Downgrade R Raymond James
Outperform → Mkt Perform Aug 12, 2024 Downgrade P Piper Sandler
Overweight → Neutral $42 → $11 -69.8% Aug 12, 2024 Downgrade J JP Morgan
Overweight → Underweight $45 → $10 -72.6% Jul 03, 2024 Downgrade B Barclays
Overweight → Equal Weight $38 → $25 -31.4% Mar 07, 2024 Resumed J JP Morgan
Overweight $80 → $45 +23.4% Dec 20, 2023 Initiated R Raymond James
Outperform $42 +15.2% Aug 03, 2023 Upgrade T TD Cowen
Market Perform → Outperform $50 +37.1% Jan 31, 2023 Resumed W Wedbush
Outperform $88 → $60 +64.6% Oct 21, 2022 Resumed J Jefferies
Buy $66 +81.0% Jan 03, 2022 Resumed J JP Morgan
Overweight $75 → $83 +127.6% Jul 26, 2021 Upgrade J JP Morgan
Neutral → Overweight $75 +105.7%
Show Previous Ratings
Nov-11-26 06:51PM
06:14PM
01:43PM
Nov-05-26 06:59AM
Nov-03-26 07:09PM
08:40AM
Loading…
Oct-30-26 08:40AM
Oct-27-26 03:14AM
Oct-12-26 08:50PM
02:32AM
Oct-09-26 09:12PM
Oct-08-26 02:31PM
01:48PM
01:20PM
(Pharmaceutical Technology)
12:01PM
12:00PM
11:23AM
Loading…
11:23AM
10:37AM
09:55AM
(The Wall Street Journal)
08:48AM
(The Wall Street Journal)
07:45AM
Oct-07-26 08:00AM
Oct-06-26 06:28AM
(Pharmaceutical Technology)
Oct-05-26 08:00AM
Sep-09-26 08:00AM
Aug-07-26 08:00AM
Aug-06-26 08:00AM
Aug-05-26 01:05AM
Aug-04-26 04:01PM
Jul-28-26 08:00AM
Jul-27-26 08:00AM
08:00AM
Loading…
Jul-22-26 08:00AM
Jul-08-26 08:00AM
Jul-01-26 08:00AM
06:53AM
Jun-30-26 07:30AM
07:17AM
Jun-09-26 05:53PM
Jun-04-26 04:20PM
Jun-01-26 04:50PM
May-28-26 04:20PM
09:18AM
May-27-26 04:20PM
08:00AM
May-26-26 08:00AM
May-21-26 01:53PM
May-20-26 12:28PM
06:30AM
May-13-26 10:58AM
08:00AM
May-12-26 04:01PM
May-08-26 08:00AM
May-05-26 04:20PM
May-01-26 03:18AM
Apr-30-26 04:01PM
Apr-28-26 04:20PM
Apr-27-26 08:00AM
Apr-16-26 08:00AM
Apr-13-26 08:00AM
Apr-08-26 08:00AM
Mar-30-26 08:00AM
Mar-11-26 05:02PM
01:06PM
Mar-06-26 08:00AM
Mar-04-26 08:00AM
Mar-02-26 08:00AM
Feb-27-26 09:49AM
01:12AM
12:06AM
Feb-26-26 07:30PM
05:30PM
04:01PM
Feb-12-26 04:01PM
08:00AM
Feb-09-26 08:00AM
Feb-03-26 10:00AM
Jan-28-26 08:00AM
Jan-27-26 12:45PM
12:10PM
Jan-16-26 08:30AM
Jan-14-26 10:18AM
Jan-13-26 08:00AM
Jan-12-26 10:14AM
Jan-08-26 04:01PM
Jan-07-26 08:00AM
Dec-31-25 10:45AM
Dec-30-25 10:41AM
Dec-18-25 08:00AM
Dec-17-25 02:19PM
Dec-16-25 02:10PM
(Investor's Business Daily)
Dec-03-25 10:23AM
08:00AM
Dec-02-25 08:00AM
Nov-26-25 04:01PM
Nov-14-25 06:00PM
Nov-11-25 08:00AM
Nov-10-25 08:09PM
Nov-07-25 12:02AM
Nov-06-25 06:30PM
06:10PM
05:06PM
(Associated Press Finance)
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RIKER LAUREN Senior Vice President, Finance Oct 08 '26 Option Exercise 32.35 6,000 194,100 68,284 Oct 09 07:07 PM RIKER LAUREN Senior Vice President, Finance Oct 08 '26 Sale 36.32 6,000 217,920 62,284 Oct 09 07:07 PM RIKER LAUREN Officer Oct 08 '26 Proposed Sale 36.32 6,000 217,920 Oct 08 10:02 AM SLONIN JONATHAN Chief Medical Officer Aug 17 '26 Sale 23.23 3,040 70,619 216,384 Aug 18 05:21 PM SLONIN JONATHAN Officer Aug 17 '26 Proposed Sale 23.23 3,040 70,619 Aug 17 11:54 AM RIKER LAUREN Senior Vice President, Finance Jun 11 '26 Sale 23.50 6,115 143,702 62,284 Jun 12 09:07 PM Ceesay Abraham Director Jun 12 '26 Proposed Sale 23.27 9,039 210,374 Jun 12 12:15 PM RIKER LAUREN Officer Jun 11 '26 Proposed Sale 23.50 6,115 143,702 Jun 11 11:28 AM WILLIAMS KRISTEN Chief Administrative Officer Jun 04 '26 Sale 22.27 10,259 228,468 167,062 Jun 05 05:57 PM WILLIAMS KRISTEN Officer Jun 04 '26 Proposed Sale 22.27 10,259 228,468 Jun 04 09:48 AM Cross Shawn Chief Financial Officer Apr 23 '26 Option Exercise 16.45 12,941 212,879 118,282 Apr 24 08:41 PM Cross Shawn Chief Financial Officer Apr 23 '26 Sale 25.16 12,941 325,596 105,341 Apr 24 08:41 PM Cross Shawn Officer Apr 23 '26 Proposed Sale 25.16 12,941 325,576 Apr 23 04:41 PM Cross Shawn Chief Financial Officer Apr 20 '26 Option Exercise 16.45 7,714 126,895 113,055 Apr 22 08:03 PM Cross Shawn Chief Financial Officer Apr 21 '26 Option Exercise 16.45 2,845 46,800 108,186 Apr 22 08:03 PM Cross Shawn Chief Financial Officer Apr 22 '26 Option Exercise 16.45 1,500 24,675 106,841 Apr 22 08:03 PM Cross Shawn Chief Financial Officer Apr 20 '26 Sale 25.14 7,714 193,930 105,341 Apr 22 08:03 PM Cross Shawn Chief Financial Officer Apr 21 '26 Sale 25.01 2,845 71,153 105,341 Apr 22 08:03 PM Cross Shawn Chief Financial Officer Apr 22 '26 Sale 25.01 1,500 37,515 105,341 Apr 22 08:03 PM Cross Shawn Officer Apr 22 '26 Proposed Sale 25.01 1,500 37,520 Apr 22 04:20 PM Cross Shawn Officer Apr 21 '26 Proposed Sale 25.01 2,845 71,149 Apr 21 04:20 PM Cross Shawn Officer Apr 20 '26 Proposed Sale 25.14 7,714 193,912 Apr 20 04:11 PM SLONIN JONATHAN Chief Medical Officer Mar 17 '26 Sale 22.82 3,261 74,416 223,640 Mar 19 05:43 PM Froimson Mark Director Mar 17 '26 Sale 21.81 500 10,905 20,136 Mar 19 05:43 PM Froimson Mark Director Mar 17 '26 Proposed Sale 21.81 500 10,905 Mar 17 02:55 PM SLONIN JONATHAN Officer Mar 17 '26 Proposed Sale 22.82 3,261 74,416 Mar 17 11:12 AM RIKER LAUREN Senior Vice President, Finance Feb 02 '26 Sale 20.81 4,000 83,240 52,313 Feb 03 06:24 PM WILLIAMS KRISTEN Chief Administrative Officer Feb 02 '26 Sale 20.53 13,137 269,703 131,303 Feb 03 06:24 PM RIKER LAUREN Officer Feb 02 '26 Proposed Sale 21.05 4,000 84,219 Feb 02 04:12 PM WILLIAMS KRISTEN Officer Feb 02 '26 Proposed Sale 20.53 13,137 269,703 Feb 02 10:55 AM RIKER LAUREN Senior Vice President, Finance Jan 05 '26 Sale 24.24 1,416 34,324 59,064 Jan 06 05:30 PM RIKER LAUREN Officer Jan 05 '26 Proposed Sale 24.24 1,416 34,324 Jan 05 11:22 AM Cross Shawn Chief Financial Officer Dec 09 '25 Option Exercise 16.45 15,896 261,489 72,146 Dec 11 09:47 PM Cross Shawn Chief Financial Officer Dec 10 '25 Option Exercise 16.45 9,104 149,761 65,354 Dec 11 09:47 PM Cross Shawn Chief Financial Officer Dec 09 '25 Sale 25.03 15,896 397,877 56,250 Dec 11 09:47 PM Cross Shawn Chief Financial Officer Dec 10 '25 Sale 25.14 9,104 228,875 56,250 Dec 11 09:47 PM Cross Shawn Officer Dec 10 '25 Proposed Sale 25.14 9,104 228,912 Dec 10 04:41 PM Cross Shawn Officer Dec 09 '25 Proposed Sale 25.03 15,896 397,837 Dec 09 04:31 PM SLONIN JONATHAN Chief Medical Officer Nov 17 '25 Sale 24.09 3,960 95,396 178,367 Nov 19 04:32 PM SLONIN JONATHAN Officer Nov 17 '25 Proposed Sale 24.09 3,960 95,396 Nov 17 10:25 AM
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Brisbane, CA.
CEO & Director Mr. Frank D. Lee
Chief Financial Officer Mr. Shawn M. Cross
J.D. Ms. Kristen Williams Esq.
Chief Medical Officer Dr. Jonathan Slonin M.D.
Chief Commercial Officer Mr. Brendan P. Teehan